Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL7542736 | 1.00 | MEN1 (0.72) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL6634229 | 0.99 | MEN1 (0.70) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL6634231 | 0.99 | MEN1 (0.70) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL7536313 | 0.88 | CYP1A2 (0.67) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL7536321 | 0.88 | CYP1A2 (0.67) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL5442776 | 0.88 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL5442781 | 0.88 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL6635547 | 0.87 | CYP1A2 (0.65) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL6635550 | 0.87 | CYP1A2 (0.65) | MEN1KMT2ACYP1A2HRH1LMNA | |
| Acetylcarnitine SCHEMBL3637963 | 0.86 | MEN1 (0.77) | MEN1KMT2ACYP1A2HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | claimed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021221741-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | LONZA CONSUMER HEALTH INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | claimed |
| EP-4125858-B1 | NUTRITIONAL COMPOSITION COMPRISING L-CARNITINE TARTRATE FOR USE IN TREATING OR PREVENTING A CORONAVIRUS INFECTION IN A MAMMAL | LONZA GREENWOOD LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | disclosed |
| EP-3154539-B1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA CONSUMER HEALTH INC (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220370393-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS | CAPSUGEL BELGIUM NV (BE) | 2022-11-24 | — | — | US | disclosed |
| US-20220370392-A1 | Method and Composition for Increasing Muscle Protein Synthesis | CAPSUGEL BELGIUM NV (BE) | 2022-11-24 | — | — | US | disclosed |
| EP-4027991-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS | Capsugel Belgium NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| EP-4027990-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS | Capsugel Belgium NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| US-10016382-B2 | Method for decreasing skeletal muscle damage and/or oxidative stress in mammals | LONZA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017106687-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS AND/OR FUNCTIONAL STRENGTH IN MAMMALS AS WELL AS METHOD OF PRODUCING A COMPOSITION | LONZA INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170173050-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS AND/OR FUNCTIONAL STRENGTH IN MAMMALS | LONZA GREENWOOD LLC | 2017-06-22 | — | — | US | disclosed |
| EP-3154539-A1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | Lonza Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015191827-A1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150359769-A1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA GREENWOOD LLC | 2015-12-17 | — | — | US | disclosed |
| EP-1202956-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | Biosalts S.r.l. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2000073258-A1 | THERAPEUTICALLY AND/OR NUTRITIONALLY ENHANCED DERIVATIVES OF ACTIVE INGREDIENTS AND ORALLY ADMINISTRABLE COMPOSITIONS CONTAINING SAME | BIOSALTS S.R.L. (IT) | 2000-12-07 | — | — | WO | disclosed |